Treatment Approach to ROS1 Rearranged NSCLC

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Treatment Approach to ROS1 Rearranged NSCLC

By Yale Cancer Center FEATURING Michael Grant

0 views

October 19, 2023

On November 15, 2023, the FDA approved repotrectinib (brand name Augtyro) for locally advanced or metastatic ROS1-positive non-small cell lung cancer.

Comments 0

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

The Use of IO Doublet in PD-L1-Negative NSCLC